« Return to News | Drug Sponsors | Ethics/Regulatory

Novartis recalls OTC drugs, temporarily closes U.S. plant

Monday, January 9, 2012 01:51 PM

Novartis is recalling several over-the-counter products such as Gas-X, Excedrin, NoDoz, and Bufferin due to inconsistent bottling, as well as broken gel caps and chipped pills.

“Mixing of different products in the same bottle could result in consumers taking the incorrect product and receiving a higher or lower strength than intended,” Novartis stated. “This could potentially result in overdose, interaction with other medications a consumer may be taking or an allergic reaction.”

The recall began the day after the FDA released a 13-page Form 483, which cited Novartis’ repeated failures to follow up on quality concerns voiced by patients. The company also failed to inform the FDA of these complaints. Issues raised in the 483 were identified in the summers of 2010 and 2011.

In addition to recalling its products, Novartis temporarily shut down its Lincoln, Neb., plant to fix and improve its manufacturing activities, expecting a $120 million one-time charge.

A full list of products and recall dates can be found at www.novartisOTC.com.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.